Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis

Huan Wang · Jing Huang · Xiaojin Yu · Shuhua Han · Xing Yan · Siqing Sun · Xiaoli Zhu

Received: 16 February 2014 / Accepted: 11 May 2014 / Published online: 8 June 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract

Background Nearly 85 % of lung-cancer-specific epidermal growth factor receptor (EGFR) sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants in exon 19 (19del). The aim of this study was to assess the role of EGFR mutation subtypes in predicting the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) and the prognosis of patients with advanced non-small cell lung cancer (NSCLC).

Method We systematically searched for eligible articles investigating the association between EGFR mutation subtypes and the efficacy of EGFR TKIs and the prognosis of patients with NSCLC. The summary risk ratio (RR) and mean difference (MD) were calculated using meta-analysis. In addition, we used variance analysis for the progression-free survival data (PFS) and used the rank sum test for the overall survival data.

Results We identified 22 eligible trials involving 1,082 patients. The objective response rate of the 19del mutation group was significantly higher than the 21L858R mutation group (RR 1.23; 95 % CI 1.12–1.36; P < 0.0001). The PFS (MD 3.55; 95 % CI 0.90–6.20; P = 0.009; MD 2.57; 95 % CI 0.51–4.62; P = 0.01) and overall survival (OS) (MD 10.52; 95 % CI 5.10–15.93; P = 0.0001) of the 19del mutation group were significantly longer than the 21L858R mutation group; the same results were observed in the variance analysis and rank sum test.

Conclusion The 19del mutation may be a more efficient clinical marker for predicting the response of patients with NSCLC to EGFR TKIs. Furthermore, patients with the 19del mutation have both a longer PFS and OS. The 19del mutation is also the prognostic factor for patients with NSCLC.

Keywords NSCLC · EGFR · EGFR TKIs · Meta-analysis

Introduction

The small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, have been widely used in the treatment of advanced non-small cell lung cancer (NSCLC) (NCCN 2014). With the IDEAL1 study proving the efficacy of gefitinib for advanced NSCLC patients as a second-line treatment in 2003 (Fukuoka et al. 2003), and the BR.21 study indicating the efficacy of erlotinib for advanced NSCLC patients with chemotherapy failure in 2005 (Tsao et al. 2005), the development of EGFR TKIs was a milestone in NSCLC treatment.

Many studies have indicated that EGFR sensitive mutations are associated with a better efficacy of EGFR TKIs. Mokita’s analysis of seven clinical trials showed that patients with EGFR mutations responded better to EGFR TKIs, having a higher objective response rate (ORR) (79.3 %) and longer progression-free survival (PFS) (10.7 months) (Morita et al. 2009). A meta-analysis of phase III clinical trials (Gao et al. 2012) (including IPASS/OPTIMAL/EURTAC) also showed that EGFR TKIs in NSCLC patients with EGFR sensitive mutations...
brought the ORR up as high as 66.6%, with a median progression-free survival (mPFS) of 9.5 months and a median overall survival (mOS) of 30.5 months, as the first-line treatment. A recent pooled analysis (Paz-Ares et al. 2010) of 54 studies demonstrated that EGFR mutations predict response to EGFR TKIs, with erlotinib and gefitinib treatment showing significantly higher mPFS times of 13.2 and 9.8 months, respectively, when compared with only 5.9 months for chemotherapy treatment alone.

EGFR mutations occur almost exclusively within exons 18–21 of the gene, which encodes the amino lobe and part of the carboxy lobe of the receptor. Nearly 85% of lung-cancer-specific EGFR mutations comprise a leucine-to-arginine substitution at position 858 (21L858R) and a deletion mutation in exon 19 that affects the conserved sequence LREA (19del) (Rosell et al. 2009). Is there any difference in response to EGFR TKIs between the two common types of patients with EGFR mutations? Several clinical studies suggested that patients with the exon 19 deletion had a better response rate, and a significantly longer PFS and OS than patients with L858R (Mitsudomi et al. 2010; Fukuoka et al. 2011). However, several other studies indicated that the difference in EGFR TKI efficacy between the two subtypes of EGFR mutations is not statistically significant (Cappuzzo et al. 2007).

We performed this meta-analysis, to compare the difference in EGFR TKI efficacy and determine the prognosis of advanced NSCLC patients with the two common subtypes of EGFR mutations (exon 19del and exon L858R), aiming to more accurately predict the response to EGFR TKIs and the prognosis for advanced NSCLC patients with activating EGFR mutations.

**Methods**

**Search strategy**

We performed a computerized search of Pubmed, Embase, and the Chinese National Knowledge Infrastructure (CNKI) database, we also manually searched the conference proceedings of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer from the year of 2000–2013 for relevant clinical trials. Reference lists from studies were also hand searched for this review. The following keywords were used: “NSCLC” or “non-small cell lung cancer” and “gefitinib or erlotinib” and “response.” There was no language restriction.

**Inclusion criteria**

1. All prospective and retrospective studies were eligible for the study pool, only the most recent publication results from the same studies were included.
2. The patients who had a diagnosis of advanced NSCLC with stage III–IV and the patients harboring activating EGFR mutations (either exon 19 deletion or L858R in exon 21).
3. All patients received EGFR TKIs (gefitinib or erlotinib) for monotherapy, first line or otherwise.
4. All the included patients were evaluated by their treatment response, PFS and OS. Response Evaluation Criteria on Solid Tumors (RECIST) criteria were used to define response, with “complete response” or “partial response” classified as “response,” and “stable” with no change, or “progressive”.

**Exclusion criteria**

1. Review, in vitro and animal experiments.
2. The objects of studies were not NSCLC patients.
3. The study of EGF mutation in peripheral blood.
4. EGFR TKIs were used as maintenance or adjuvant therapy, or as sequential treatment with chemotherapy.

**Quality assessment and data extraction**

The randomized controlled studies were assessed in strict accordance with the Jadad scale (Jadad et al. 1996), and the other studies were assessed in terms of the Newcastle-Ottawa Scale (NOS) (Wells et al. 2012; Stang 2010). To avoid evaluation deviation, two reviewers performed the assessment independently and discussed in order to reach an accordance when the information was unsatisfactory.

The following data were collected from each study: (1) general information: first author’s surname, publication time, source of the trial and the research type. (2) Features of the literature: clinical stage (AJCC staging), total numbers of the EGFR mutation types. (3) Evaluation indexes: ORR, PFS or TTP, and OS (Parmar et al. 1998).

**Data analysis and statistical methods**

The meta-analysis of risk ratios (RRs) for the objective responses to treatment and the meta-analysis of mean differences (MDs) for PFS and OS were calculated using Review Manager (RevMan), version 5.2 (The Nordic Cochrane Centre, Copenhagen, Denmark) (The Cochrane Collaboration 2008). A statistical test with a P value <0.05 was considered significant. RR > 1 reflects a better overall response rate
in the exon 19del arm, MD > 1 reflects fewer deaths or progression in the exon 19del arm and vice versa. In each meta-analysis, Cochran’s Q statistic and $I^2$ statistics were calculated first in order to assess the heterogeneity among the proportions of the included trials. In case the $P$ value was found to be <0.05, the assumption of homogeneity was deemed invalid and a random effects model was reported. Otherwise, a fixed effects model was reported. All $P$ values were two sided. All CIs had a two-sided probability coverage of 95 %. If the study provided medians and interquartile ranges instead of means and SDs, we inputed the means and SDs as described by Hozo et al. (2005). When the literature failed to provide the standard deviation, we estimated it with the maximum and minimum values of similar studies from the included literature.

At the same time, we performed variance analyses for the progression-free survival of both exon 19del and exon 21L858R arms and used Mann–Whitney $U$ test for the overall survival of both exon 19del and exon 21L858R arms, with a $P$ value <0.05 considered to be significant. The calculations were performed by SPSS 18.0 (SPSS Inc., USA).

**Results**

**Study identification**

As shown in the NSCLC flow chart (Fig. 1), our initial search yielded 950 potentially relevant published articles. A review of the titles and abstracts of these articles resulted in 145 promising articles. These remaining 145 articles were selected for analysis and evaluated in greater detail by reviewing the full articles. After exclusion of the studies that did not meet the inclusion criteria, 22 studies with 1,082 patients were included in the meta-analysis, 593 patients with the exon 19del mutation and 489 patients with the exon 21L858R mutation. The characteristics of the eligible studies are summarized in Table 1.

**Response rate**

Data for the ORR were available in 19 trials, with 12 prospective trials and 7 retrospective trials, respectively. The $I^2$ statistic in the fixed effects model did not demonstrate significant heterogeneity in the results ($I^2$ 37 %; $P = 0.06$); the fixed effects model was used to pool the risk ratio for the included studies. Analysis of this data demonstrated that the ORR of the exon 19del group was 76.44 % (318/416), which was higher than the 60.66 % (202/333) found for the exon 21L858R group, and the difference was statistically significant. (RR = 1.23; 95 % CI 1.12–1.36; $P < 0.0001$) (Fig. 2).

Furthermore, subgroup analysis revealed that the ORR was significantly different between the two groups (prospective trials: RR = 1.22, 95 % CI 1.10–1.36; retrospective trials: RR = 1.26, 95 % CI 1.03–1.53).

**Progression-free survival**

Data for the PFS were available in thirteen trials, with seven prospective trials and six retrospective trials, respectively. The standard deviation could be obtained in five trials; the range of the standard deviation values was 5.59–14.7 in prospective trials and 2.97–9.94 in retrospective trials.

We set the standard deviation to the minimum value of 5.59 for the other four prospective trials, and the minimum value 2.97 was used for the other four retrospective trials. Because the $I^2$ statistic in the fixed effects model demonstrated statistically significant heterogeneity in the results ($I^2$ 92 %; $P < 0.0001$), a random effects model was used to pool the mean difference for the included studies. As Fig. 3 demonstrates, patients with exon 19del mutation had a statistically significant longer PFS than patients with exon 21L858R mutations (MD 3.55; 95 % CI 0.90–6.20; $P = 0.009$). As the subgroup analysis shows, in prospective trials, subgroup patients with the exon 19del mutation had a longer PFS than patients with the exon 21L858R mutations, but the difference was not statistically significant (MD 2.68; 95 % CI −1.02 to 6.38; $P = 0.16$; $I^2 = 84$ %; random effects model). However, patients with the exon 19del mutation had a statistically significant longer PFS than patients with the exon 21L858R mutations in the retrospective trials subgroup (MD 4.51; 95 % CI 0.46–8.56; $P = 0.03$; $I^2 = 96$ %, random effects model).
Similarly, we repeated the analysis with the standard deviation set to the maximum value of 14.7 for the other four prospective trials, and the maximum value 9.94 for the other for retrospective trials. Because the $I^2$ statistic in the fixed effects model demonstrated statistically significant heterogeneity in the results ($I^2 = 42\ %; P = 0.05$), a random effects model was used to pool the mean difference for the included studies. As Fig. 4 demonstrates, patients with the exon 19del mutation had a statistically significant longer PFS than patients with the exon 21L858R mutation (MD 2.57; 95 % CI 0.51–4.62; $P = 0.01$). As the subgroup analysis shows, in the prospective trials, subgroup patients with exon 19del mutation had a longer PFS than patients with exon 21L858R mutations, but the difference was not statistically significant (MD 1.42; 95 % CI $-1.02$ to $3.87$; $P = 0.25$; $I^2 = 3\ %$, random effects model). However, patients with the exon 19del mutation had a statistically significant longer PFS than patients with the exon 21L858R mutations in the retrospective trials subgroup (MD 3.82, 95 % CI 0.26–7.39; $P = 0.04$; $I^2 = 66\ %$, random effects model).

Overall survival (OS)

Data for the OS were available in three of the retrospective trials. The standard deviation for the OS could be obtained in Xu’s trial. But it was necessary to set the value for the other two trials. The $I^2$ statistic in the fixed effects model did not demonstrate significant heterogeneity in the results ($I^2 = 0\ %; P = 0.42$), so the fixed effects model was used to pool the mean difference for the included studies. As shown in Fig. 5, patients with exon 19del mutation had a statistically significant longer OS than patients with exon 21L858R mutation (MD 10.52; 95 % CI: 5.10–15.93; $P = 0.0001$).

Publication bias

The funnel plot for the overall pooled analysis of the association between subtypes of EGFR mutations, and response (Fig. 6a) revealed no evidence of publication bias, with a symmetrical distribution of study results around the pooled measurement of effect. Moreover, the funnel plot for the

| First author (year) | Race | Clinical stage | Number | Treat line | Treatment | Type of article | Score |
|---------------------|------|----------------|--------|------------|------------|----------------|-------|
| Sunaga et al. (2007) | A    | III-IV         | 16     | 3          | Mix        | Pro            | 6     |
| Yoshida et al. (2007) | A    | III-B-IV       | 8      | 13         | Mix        | Pro            | 8     |
| Sequist et al. (2008) | C    | IIIB-IV        | 17     | 9          | 1          | Pro            | 7     |
| Yang et al. (2008)   | A    | III-B-IV       | 20     | 23         | 1          | Pro            | 6     |
| Asahina et al. (2006) | A    | III-B-IV       | 13     | 3          | Mix        | Pro            | 7     |
| Fukuoka et al. (2011) | A    | III-B-IV       | 66     | 64         | 1          | RCT            | 5     |
| Maemondo et al. (2010) | C   | III-B-IV       | 58     | 42         | 1          | RCT            | 4     |
| Jackman et al. (2006) | C    | IIIB-IV        | 22     | 10         | 1          | Pro            | 7     |
| Sutani et al. (2006) | A    | III-B-IV       | 20     | 7          | Mix        | Pro            | 8     |
| Cappuzzo et al. (2007) | C    | IIIB-IV        | 17     | 7          | $\geq 2$   | Pro            | 6     |
| Tamura et al. (2008) | A    | III-B-IV       | 14     | 17         | Mix        | Pro            | 7     |
| Sugio et al. (2009)  | A    | III-B-IV       | 7      | 10         | 1          | Pro            | 6     |
| Takano et al. (2007) | A    | III-B-IV       | 49     | 36         | Mix        | Retro          | 6     |
| Chou et al. (2005)   | A    | III-B-IV       | 11     | 12         | Mix        | Retro          | 5     |
| Ichihara et al. (2007) | A   | III-B-IV       | 16     | 14         | Mix        | Retro          | 7     |
| Pallis et al. (2007) | C    | IIIB-IV        | 6      | 3          | $\geq 2$   | Retro          | 5     |
| Wu (2010)            | A    | IIIB-IV        | 34     | 23         | $\geq 2$   | Retro          | 5     |
| Xu et al. (2009)     | A    | IIIB-IV        | 11     | 6          | $\geq 2$   | Retro          | 7     |
| Hirsch et al. (2007) | C    | IIIB-IV        | 11     | 31         | Mix        | Retro          | 7     |
| 马 (2013)            | A    | IIIB-IV        | 29     | 36         | Mix        | Retro          | 4     |
| Mitsudomi et al. (2010) | A   | IIIB-IV        | 87     | 85         | 1          | RCT            | 5     |
| Rosell et al. (2009) | C    | IIIB-IV        | 57     | 29         | 1          | Pro            | 8     |
overall pooled analysis of the association between types of EGFR mutations, and PFS (Fig. 6b) also revealed no evidence of publication bias. The mean of the pooled effect was positive which indicated a potential publication bias in favor of more positive studies. However, the evaluation of publication bias using the funnel plot approach was somewhat limited by the small number of studies identified for inclusion in the pooled analyses.

Variance analysis

We, respectively, compared the PFS of 767 patients and the OS of 123 patients through variance analysis, using SPSS software.

As shown in Table 2, the PFS data are normally distributed ($P > 0.05$). The average PFS was 11.1 months in patients with the exon 19del mutation and 8.7 months in patients with the exon 21L858R mutation, this difference is statistically significant ($P < 0.05$). As the results of the rank and $U$ test show, the overall survival data had a non-normal distribution ($P < 0.001$), and the average overall survival in patients with the exon 19del mutation was 23.9 and 13.0 months for patients with the exon 21L858R mutation, this difference is also statistically significant.

Discussion

The correlation of EGFR TKI efficacy and EGFR mutations subtypes is the important factor in most of the large phase III clinical trials in NSCLC patients with EGFR sensitive mutations, but the results are difficult to combine. According to analyses of the five US and European clinical trials that assessed first-line TKI treatment,
Fig. 3 Forest plot of PFS among patients with EGFR 19del or 21L858R mutations with minimum SD. The squares and horizontal lines correspond to the study-specific MD and 95% CI. The area of the squares reflects the weight. The diamond represents the summary RR and 95% CI.

Fig. 4 Forest plot of PFS among patients with EGFR 19del or 21L858R mutations with maximum SD. The squares and horizontal lines correspond to the study-specific MD and 95% CI. The area of the squares reflects the weight. The diamond represents the summary RR and 95% CI.
patients with the exon 19 deletion have a significantly longer progression-free and overall survival time than patients with L858R (30.8 vs. 14.8 months; \( P < 0.0001 \)) (Morita et al. 2009). Studies on North American patients indicated that those with deletions of exon 19 in the EGFR have a better response rate, progression-free survival and overall survival after EGFR tyrosine kinase inhibitor treatment than do those with the L858R mutation in exon 21 (Jackman et al. 2006; Riely et al. 2006). A Spanish study led by Rosell also indicated that patients with the 19del mutation had a better response than those with the L858R mutation (odds ratio, 3.08; 95 % CI 1.63–5.81; \( P = 0.001 \)); however, there was no significant difference in the progression-free survival time with respect to mutation type (Rosell et al. 2009). The results of the IPASS study showed that compared with the patients with the L858R mutation, the PFS of patients with the 19del mutation was not statistically different (HR 0.55; 95 % CI 0.35–0.87); however, the ORR was higher (84.8 %), but the difference was not statistically significant (OR 1.41; 95 % CI 0.65–3.05) (Fukuoka et al. 2011). The same results were acquired from WJTOG3405 and EURTAC studies (Mitsudomi et al. 2010). Differences in the results of these studies may be related to the sample count. For this reason, we systematically evaluated the differences between the two common EGFR mutations and the efficacy of EGFR TKIs. Our analysis adds to our understanding of the importance of the influence of EGFR mutations on the efficacy of EGFR TKI. The results of this meta-analysis comparing the difference in efficacy of EGFR TKI in advanced NSCLC for the EGFR 19del and 21L858R mutations, confirms that the EGFR 19del mutations when treated with EGFR TKI show a better response rate and progression-delaying effect than the EGFR 21L858R mutations.

Table 2  Variance analysis for the progression-free survival data, and rank and sum test—nonparametric (U test) for the overall survival data

|        | 19del | 21L858R | \( F (P \text{ value}) \) | \( P \text{ value} \) (U test) |
|--------|-------|---------|--------------------------|-------------------------------|
| PFS (month) | 11.1 | 8.7 | 3.673 (\( P > 0.05 \)) | 0.000 |
| OS (month)  | 23.9 | 13.0 | 11.283 (\( P < 0.001 \)) | \( P < 0.05 \) |
The results of this pooled analysis highlight the idea that the exon 19del mutation is a better indicator of strong efficacy in EGFR TKI treatment, which is an improvement over findings in patients with lung cancer that have been reported previously. These results also contribute to evidence-based medicine in clinical work. Screening for EGFR mutations is warranted and should be performed before beginning therapy with EGFR TKIs, since the exon 19del mutation implies a better outcome than the L858R mutation.

As our meta-analysis results have shown, the subgroup analysis showed that there was no statistically significant difference in PFS, the possible reason may be that the small sample size results in the lack of statistical significance. The number of subgroups in the included literature is too few, totaling only seven prospective studies and six retrospective studies. Moreover, only three cases in the literature were included in the pooled analysis of OS, so the sample number was low. Unfortunately, most of the prospective and retrospective studies failed to obtain the overall survival data, so the evaluation of the difference in OS needs further verification.

We estimated the standard deviation in order to evaluate the data of progression-free survival and overall survival for studies with a poor level of evidence-based medicine. Toward this end, we compared the difference in the mean for the two types of EGFR mutations and overall survival in patients using SPSS software. The results showed that progression-free survival and overall survival in patients with the exon 19del mutation were significantly longer than patients with the exon 21L858R mutation, which is in accordance with the results of the meta-analysis.

Comprehensive literature was included in this pooled analysis which contains both prospective and retrospective studies, and the number of objects was determined to be sufficiently large. The ORR, progression-free survival and overall survival were all selected to evaluate the difference in EGFR TKI efficacy between exon 19del and 21L858R mutations; our evaluation indicators are comprehensive thereby. However, our evaluation has the following limitations; firstly, due to lack of research about the relationship between EGFR mutation type and the efficacy of EGFR TKI, all the data came from their subgroups, which could lead to the data being incomplete. Secondly, the instability problems of the retrospective studies also influenced the quality of the system analysis.

Conclusion

The results of this system evaluation suggest that in III-IV NSCLC patients with EGFR mutations, patients with the exon 19 deletion have a better response rate, and a significantly longer progression-free survival and overall survival than patients with the L858R mutation. Hence, the type of EGFR mutation has predictive value for EGFR TKI efficacy, and patients with the exon 19del mutation show a more prominent preponderance in efficacy for EGFR TKIs. The difference may be related to the different biological activities of EGFR mutations. The mechanism is not entirely clear, so further exploration is needed at the molecular level in the future.

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Asahina H, Yamazaki K, Kinoshita I et al (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95(8):998–1004
Cappuzzo F, Ligorio C, Janne PA et al (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non–small-cell lung cancer: the ONCO-BELL trial. J Clin Oncol 25(16):2248–2255
Chou TY, Chiu CH, Li LH et al (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11(10):3750–3757
Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21(12):2237–2246
Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874
Gao G, Ren S, Li A et al (2012) Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 131(5):E822–E829
Hirsch FR, Varella-Garcia M, Cappuzzo F et al (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4):752–760
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13
Ichihara S, Toyooka S, Fujiwara Y et al (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120(6):1239–1247
Jackman DM, Yeap BY, Sequist LV et al (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12(13):3908–3914

σ Springer
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388
Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128
Morita S, Okamoto I, Kobayashi K et al (2009) Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15(13):4493–4498
NCCN clinical practice guidelines in oncology: non-small cell lung cancer version 2. 2014
Pallis AG, Voutsina A, Kalikaki A et al (2007) ‘Classical’ but not ‘other’mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97(11):1560–1566
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
Paz-Ares L, Soulières D, Melezinek I et al (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 14(1–2):51–69
Riely GJ, Pao W, Pham D et al (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839–844
Roslley M, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967
Sequist LV, Martins RG, Spigel D et al (2008) First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic EGFR mutations[J]. J Clin Oncol 26(15):2442–2449
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta analyses. Eur J Epidemiol 25(9):603–605
Sugio K, Uramoto H, Onitsuka T et al (2009) Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 64(3):314–318
Sunaga N, Tomizawa Y, Yanagitani N et al (2007) Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56(3):383–389
Sutani A, Nagai Y, Udagawa K et al (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95(11):1483–1489
Takano T, Ohe Y, Tsuta K et al (2007) Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non–small cell lung cancer treated with gefitinib. Clin Cancer Res 13(18):5385–5390
Tamura K, Okamoto I, Kashii Y et al (2008) Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98(5):907–914
Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 353(2):133–144
Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses, [2012-06-15]
Wu M et al (2010) EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 67(3):343–347
Xu JM, Han Y, Duan HQ et al (2009) EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non–small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 135(6):771–782
Yang CH, Yu CJ, Shih JY et al (2008) Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non–small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26(16):2745–2753
Yoshida K, Yatabe Y, Park JY et al (2007) Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2(1):22–28
马宇翔, 黄岩, 赵洪云 等. 晚期 EGFR 突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析. 中国肺癌杂志, 2013, 16(4):203–210